Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CytomX Therapeutics stock | $7.19

Own CytomX Therapeutics stock in just a few minutes.

Fact checked

CytomX Therapeutics, Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 158 staff and has a trailing 12-month revenue of around USD$92.3 million.

How to buy shares in CytomX Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CytomX Therapeutics. Find the stock by name or ticker symbol: CTMX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CytomX Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CytomX Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CytomX Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CytomX Therapeutics share price

Use our graph to track the performance of CTMX stocks over time.

CytomX Therapeutics shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$7.19
52-week rangeUSD$3.595 - USD$15.44
50-day moving average USD$7.4476
200-day moving average USD$7.4006
Wall St. target priceUSD$12.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.2

Buy CytomX Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CytomX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CytomX Therapeutics price performance over time

Historical closes compared with the close of $7.19 from 2020-12-09

1 week (2021-01-12) -5.89%
1 month (2020-12-18) -8.06%
3 months (2020-10-19) 7.47%
6 months (2020-07-17) -16.64%
1 year (2020-01-17) -3.62%
2 years (2019-01-18) -57.10%
3 years (2018-01-19) 25.55
5 years (2016-01-19) 12.61

CytomX Therapeutics financials

Revenue TTM USD$92.3 million
Gross profit TTM USD$57.5 million
Return on assets TTM -11.9%
Return on equity TTM -82.41%
Profit margin -58.13%
Book value $1.04
Market capitalisation USD$343 million

TTM: trailing 12 months

Shorting CytomX Therapeutics shares

There are currently 3.7 million CytomX Therapeutics shares held short by investors – that's known as CytomX Therapeutics's "short interest". This figure is 7.2% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting CytomX Therapeutics shares can be evaluated.

CytomX Therapeutics's "short interest ratio" (SIR)

CytomX Therapeutics's "short interest ratio" (SIR) is the quantity of CytomX Therapeutics shares currently shorted divided by the average quantity of CytomX Therapeutics shares traded daily (recently around 538923.82352941). CytomX Therapeutics's SIR currently stands at 6.8. In other words for every 100,000 CytomX Therapeutics shares traded daily on the market, roughly 6800 shares are currently held short.

However CytomX Therapeutics's short interest can also be evaluated against the total number of CytomX Therapeutics shares, or, against the total number of tradable CytomX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CytomX Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 CytomX Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0667% of the tradable shares (for every 100,000 tradable CytomX Therapeutics shares, roughly 67 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CytomX Therapeutics.

Find out more about how you can short CytomX Therapeutics stock.

CytomX Therapeutics share dividends

We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.

CytomX Therapeutics share price volatility

Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $3.595 up to $15.44. A popular way to gauge a stock's volatility is its "beta".

CTMX.US volatility(beta: 0.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.7486. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).

CytomX Therapeutics overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site